Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
A group of specialists at the National Cancer Institute recently issued a
report calling for a redefinition of the word "cancer," suggesting that it no longer be applied
to certain premalignant and non-lethal conditions. Such a change, the panel wrote, may ease the fears of patients, making them less inclined to seek unnecessary and potentially harmful treatments. The findings reinforce
earlier studies by Dana-Farber physicians and others.
An example of this kind of condition is
ductal carcinoma in situ (DCIS), in which cancerous cells are confined to the milk ducts of the breast. It is the most common form of non-invasive breast cancer, found in more than 60,000
women in the U.S. each year, according to the American Cancer Society.
In this video, Eric Winer, MD, former chief of the
Division of Breast Oncology at the Susan F. Smith Center for Women's Cancers at Dana-Farber, answers some common questions about DCIS and its treatment.
New Patient Appointments
For adults: 877-442-3324For children: 888-733-4662